Argus
•
Apr 15, 2026
TGTX: Raising target price to $36.00
Summary
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercial
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Merck & Co., Inc.
May 01, 2026
•
MRK
Analyst Report: AbbVie Inc.
Apr 29, 2026
•
ABBV
Daily – Vickers Top Buyers & Sellers for 04/29/2026
Apr 29, 2026
•
BLK, WULF, VMI, ABT, MSCI, LW, CHTR, NBP, ELF
ARWR: Lowering target price to $74.00
Apr 29, 2026
•
ARWR
SRPT: What does Argus have to say about SRPT?
Apr 29, 2026
•
SRPT
